

# Inducible Ischemia and the Risk of Recurrent Cardiovascular Events in Outpatients With Stable Coronary Heart Disease

## *The Heart and Soul Study*

Anil K. Gehi, MD; Sadia Ali, MD, MPH; Beeya Na, MPH; Nelson B. Schiller, MD; Mary A. Whooley, MD

**Background:** Current guidelines do not recommend routine cardiac stress testing in patients with stable coronary heart disease (CHD) unless they report symptoms of angina. Our objective was to compare the prognosis of self-reported angina symptoms, inducible ischemia, or both in patients with stable CHD.

**Methods:** We measured self-reported angina by questionnaire and inducible ischemia using treadmill stress echocardiography in 937 outpatients with stable CHD. We used Cox proportional hazard models, adjusted for traditional cardiovascular risk factors, to evaluate the independent association of angina and inducible ischemia with CHD events (myocardial infarction or CHD death) during a mean of 3.9 years of follow-up.

**Results:** Of the study participants, 129 (14%) had angina alone, 188 (20%) had inducible ischemia alone, and 40 (4%)

had both angina and ischemia. Recurrent CHD events occurred in 7% of participants without angina or inducible ischemia, 10% of those with angina alone, 21% of those with inducible ischemia alone, and 23% of those with both angina and inducible ischemia ( $P < .001$ ). The presence of angina alone was not associated with recurrent CHD events (adjusted hazard ratio, 1.4; 95% confidence interval, 0.7-2.9) ( $P = .31$ ). However, the presence of inducible ischemia without self-reported angina strongly predicted recurrent CHD events (adjusted hazard ratio, 2.2; 95% CI, 1.4-3.5) ( $P = .005$ ).

**Conclusions:** We found that 24% of patients with stable CHD had inducible ischemia, and more than 80% of these patients did not report angina. The presence of inducible ischemia without self-reported angina is associated with a greater than 2-fold increased rate of recurrent CHD events.

*Arch Intern Med.* 2008;168(13):1423-1428

**C**URRENT GUIDELINES DO not recommend routine cardiac stress testing in asymptomatic patients with known coronary heart disease (CHD).<sup>1</sup> However, the presence of asymptomatic ischemia has been shown to predict adverse outcomes in patients following coronary artery bypass grafting<sup>2</sup> or percutaneous coronary revascularization<sup>3</sup> and in diabetic patients with CHD.<sup>4</sup> Some have suggested that ischemia-guided therapy may improve prognosis in patients with stable CHD<sup>5</sup> and that we should consider relief of myocardial ischemia rather than relief of angina symptoms as the goal of therapy.<sup>6,7</sup> Previous studies have found that inducible ischemia with or without angina is predictive of incident adverse cardiovascular events,<sup>8,9</sup> but it is unknown whether inducible ischemia in the absence of self-reported angina predicts recurrent events in patients with established CHD.<sup>10</sup>

We previously demonstrated that 24% of outpatients with stable CHD had inducible ischemia by exercise stress echocardiography, and most of these patients did not report symptoms of angina.<sup>11</sup> In

the present study, we sought to compare the risk of recurrent CHD events associated with angina symptoms or inducible ischemia in outpatients with stable CHD. We assessed self-reported angina by questionnaire and measured inducible ischemia by exercise stress echocardiography in 937 outpatients with known CHD, who were participating in the Heart and Soul Study. We followed participants for a mean of 3.9 years to determine the risk of recurrent CHD events (myocardial infarction [MI] or CHD death) associated with angina, inducible ischemia, or both.

## METHODS

### PARTICIPANTS

The Heart and Soul Study is a prospective cohort study of psychosocial risk factors and cardiovascular outcomes in patients with established CHD. Details regarding our recruitment procedures have previously been published.<sup>11-14</sup> Briefly, we enrolled outpatients with documented CHD from 2 Veterans Affairs Medical Centers (San Francisco and Palo Alto, California), 1 university medical center (University

**Author Affiliations:** Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia (Dr Gehi); Veterans Affairs Medical Center, San Francisco, California (Drs Ali, Schiller, and Whooley and Ms Na); and Departments of Medicine (Drs Schiller and Whooley) and Epidemiology (Dr Whooley), University of California, San Francisco.

of California, San Francisco), and 9 community health clinics in northern California. The presence of CHD was defined by having at least 1 of the following: a history of MI, angiographic evidence of at least 50% stenosis in 1 or more major coronary vessels, prior evidence of exercise-induced ischemia by electrocardiography (EKG) or nuclear perfusion imaging, or a history of percutaneous or surgical coronary artery revascularization. Patients were excluded if they were unable to walk 1 block, had an acute coronary syndrome within the prior 6 months, or were planning to move from the local area within 3 years.

A total of 1024 participants were enrolled in the study between September 2000 and December 2002. Of the 1024 participants, 549 (54%) had a history of MI (based on inpatient *International Classification of Diseases, Ninth Revision [ICD-9]* codes), 237 (23%) had a history of revascularization (based on inpatient *ICD-9* codes) but no history of infarction, and 238 (23%) had a diagnosis of coronary disease documented by their physician (based on outpatient *ICD-9* codes and review of medical records). All participants completed a day-long baseline study appointment that included a comprehensive medical history questionnaire and an exercise stress echocardiogram. Of the 1024 participants, 87 were unable to complete the exercise treadmill stress echocardiogram for orthopedic or other reasons, leaving 937 participants for this analysis. Of these 937 participants, 496 (53%) had a history of MI, 504 (54%) had a history of revascularization, and 228 (24%) had a history of CHD based on prior evidence of exercise-induced ischemia or an abnormal coronary angiogram. The protocol was approved by the appropriate institutional review boards, and all participants provided written informed consent.

## INDUCIBLE ISCHEMIA

We assessed the presence of inducible cardiac ischemia using exercise treadmill testing with stress echocardiography.<sup>15</sup> Participants were instructed to fast for at least 4 hours prior to exercise, except for taking their usual medications as prescribed. We performed a symptom-limited, graded exercise treadmill test according to a standard Bruce protocol. Participants were asked to walk on a treadmill beginning at a workload of 20 to 30 W and increasing by 20 to 30 W every 3 minutes until reaching dyspnea, symptom-limited fatigue, or chest discomfort or showing EKG changes suggestive of ischemia. To achieve maximum heart rate, participants who were unable to continue the standard Bruce protocol (for orthopedic or other reasons) were switched to slower settings on the treadmill and encouraged to exercise for as long as possible.

We performed resting and stress echocardiography using an Acuson Sequoia Ultrasound System (Siemens Medical Solutions USA Inc, Malvern, Pennsylvania), with a 3.5-MHz transducer. Before exercise, standard 2-dimensional parasternal long-axis and short-axis and apical 2-chamber and 4-chamber views were obtained and planimeted using a computerized digitization system to determine end-diastolic and end-systolic left ventricular (LV) volume and to calculate LV ejection fraction. At peak exercise, parasternal long-axis and short-axis as well as apical 2-chamber and 4-chamber views were used to detect the development of LV wall motion abnormalities. Inducible ischemia was defined as the presence of new wall motion abnormalities at peak exercise that were not present at rest. The results from stress echocardiography were interpreted by a single expert cardiologist (N.B.S.), who was blinded to the presence of self-reported angina.

## ANGINA SYMPTOMS

We determined angina frequency using the question<sup>16</sup>: “Over the past 4 weeks, on average, how many times have you had chest

pain, chest tightness, or angina?” Possible responses were none over the past 4 weeks, less than once a week, 1 to 2 times per week, 3 or more times per week, 1 to 3 times per day, or 4 or more times per day. Initially, we categorized participants as having “no angina” (none or less than once a week), “weekly angina” (1-2 times per week or more), or “daily angina” (1 or more times per day). However, too few participants reported daily angina (n=24) to power a separate category, so we instead dichotomized participants as having weekly angina (1-2 times per week or more) or no angina (none or less than once per week).

## OUTCOME VARIABLE

The outcome variable was nonfatal MI or CHD death. We conducted annual telephone follow-up interviews with participants (or their proxy) to ask about death or hospitalizations. For any identified event, 2 independent and blinded adjudicators reviewed medical records, EKGs, death certificates, and coroner's reports. If both adjudicators agreed on the outcome classification, their classification was binding. If there was disagreement in the classification, they conferred, reconsidered their classification, and, if necessary, requested consultation from a third adjudicator. All adjudicators were blinded to the presence of self-reported angina and ischemia by stress echocardiography.

Nonfatal MI was defined as the presence of cardiac biomarkers in a setting in which signs, symptoms, and/or EKG findings suggested acute cardiac ischemia, as outlined by standard diagnostic criteria.<sup>17</sup> Death was considered CHD death if the participant died during the same hospitalization in which an acute MI was documented or if the participant experienced sudden CHD death, defined as an unexpected, otherwise unexplained death within 1 hour of the onset of terminal symptoms. To evaluate whether the prognosis of inducible ischemia varied by whether the participant underwent revascularization, we defined revascularization as coronary artery bypass grafting or percutaneous transluminal coronary angioplasty with or without placement of an intracoronary stent during the follow-up period. Revascularization was not included as an outcome variable.

## OTHER VARIABLES

Age, sex, ethnicity, medical history, smoking status, alcohol use, and physical activity were determined by questionnaire. We measured weight and height and calculated body mass index (calculated as weight in kilograms divided by height in meters squared). Participants were instructed to bring their medication bottles to the study appointment, and study personnel recorded all current medications. Fasting serum samples were obtained for measurements of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glycosylated hemoglobin, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Creatinine clearance was estimated using a 24-hour urine collection. Left ventricular ejection fraction was calculated using a resting echocardiogram as described in the “Inducible Ischemia” subsection. Systolic and diastolic blood pressure was measured using a standard sphygmomanometer.

## STATISTICAL ANALYSIS

Differences in characteristics between participants with and without exercise-induced ischemia were compared using 2-tailed *t* tests for continuous variables and  $\chi^2$  tests for dichotomous variables. We then used multivariate Cox proportional hazards models to calculate the rate of nonfatal MI or CHD death in those with or without weekly angina and in those with or without inducible ischemia. To determine the independent effects of

angina and inducible ischemia on cardiovascular outcomes, we adjusted these models for the following covariates, which were selected a priori because they were associated with inducible ischemia or known to predict recurrent CHD events: age, sex, race, history of MI, history of heart failure, glycosylated hemoglobin level, creatinine clearance, LV ejection fraction, systolic blood pressure, diastolic blood pressure, and log C-reactive protein level. Given the strong association of log NT-proBNP with recurrent cardiovascular events in this cohort,<sup>18</sup> we further adjusted for NT-proBNP to see whether NT-proBNP levels might be in the pathway between ischemia and recurrent events. Finally, we assessed the risk of nonfatal MI or CHD death in participants with inducible ischemia, stratified by whether they underwent elective revascularization. For these analyses, we report unadjusted and adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). All analyses were performed using SAS version 9.1 statistical software (SAS Institute Inc, Cary, North Carolina)

## RESULTS

Of the 937 participants, 228 (24%) had exercise-induced ischemia by treadmill testing at the baseline examination. Compared with participants who did not have inducible ischemia, those with inducible ischemia were older, more likely to be male, and more likely to be white (**Table 1**). Those with inducible ischemia were more likely to have a history of MI or congestive heart failure and more likely to be taking a renin-angiotensin inhibitor. Participants with inducible ischemia also had higher glycosylated hemoglobin levels, lower creatinine clearance, higher NT-proBNP level, lower ejection fraction, and lower diastolic blood pressure. Of the 228 participants with inducible ischemia, 20 (18%) reported weekly or more angina. Thus, 82% of patients with inducible ischemia did not report daily or weekly angina.

Participants were followed for a mean of 3.9 years (range, 0.09-5.7 years). Eight participants (<1%) were lost to follow-up, leaving 929 for the analysis. Among the 228 participants with inducible ischemia, 48 (21%) developed nonfatal MI or CHD death, compared with 55 of the 701 participants (8%) without inducible ischemia (unadjusted HR, 2.9; 95% CI, 1.9-4.2) ( $P < .001$ ). This association remained strong after adjustment for age, sex, race, history of MI, history of heart failure, glycosylated hemoglobin level, creatinine clearance, LV ejection fraction, systolic blood pressure, diastolic blood pressure, and log C-reactive protein level (HR, 2.2; 95% CI, 1.4-3.3) ( $P < .001$ ).

Among the 169 participants who self-reported weekly or more angina, 22 (13%) developed nonfatal MI or CHD death, compared with 81 of the 760 (11%) participants without weekly angina (HR, 1.3; 95% CI, 0.8-2.0) ( $P = .31$ ). Results were similar after multivariate adjustment for age, sex, race, history of MI, history of congestive heart failure, glycosylated hemoglobin level, creatinine clearance, LV ejection fraction, systolic blood pressure, diastolic blood pressure, and log C-reactive protein level (HR, 1.4; 95% CI, 0.9-2.4) ( $P = .20$ ). Even when patients who stopped the treadmill due to chest pain were included in the weekly angina category, the presence of angina did not predict MI or CHD death (adjusted HR, 1.3; 95% CI, 0.6-2.6) ( $P = .51$ ).

When stratifying the risk of CHD events by both self-reported angina and inducible ischemia, 572 participants

**Table 1. Baseline Characteristics of 937 Study Participants With Known Coronary Heart Disease, Stratified by the Presence of Inducible Ischemia**

Characteristic	Ischemia (n=228)	No Ischemia (n=709)	P Value
Age, mean (SD), y	70 (10)	66 (11)	<.001
Male sex, No. (%)	200 (88)	580 (82)	.04
White race, No. (%)	157 (69)	412 (58)	.004
History, No (%)			
Hypertension	162 (71)	493 (70)	.70
Myocardial infarction	150 (66)	346 (49)	<.001
Congestive heart failure	56 (25)	100 (14)	<.001
Stroke	39 (17)	88 (12)	.08
Diabetes	64 (28)	169 (24)	.20
Coronary revascularization	147 (64)	415 (59)	.12
CABG	112 (49)	232 (33)	<.001
PCI	82 (36)	290 (41)	.17
Current smoking, No. (%)	40 (18)	143 (20)	.37
Regular alcohol use, No. (%)	60 (26)	214 (30)	.25
Physically active, No. (%)	147 (64)	465 (66)	.72
BMI, mean (SD)	28 (5)	28 (5)	.15
Medications, No. (%)			
β-Blocker	139 (61)	406 (57)	.32
Statin	153 (67)	458 (65)	.49
Renin-angiotensin inhibitor	139 (61)	343 (48)	<.001
Aspirin	182 (80)	554 (78)	.59
Laboratory values, mean (SD)			
Total cholesterol, mg/dL	177 (41)	177 (42)	.94
HDL-C, mg/dL	46 (16)	46 (13)	.98
LDL-C, mg/dL	104 (33)	103 (33)	.93
Glycosylated hemoglobin, %	6.2 (1.3)	5.9 (1.1)	<.001
Creatinine clearance, mL/min	74 (26)	85 (28)	<.001
Log C-reactive protein, mg/L	0.08 (0.13)	0.07 (0.13)	.22
Log NT-proBNP, pg/mL	5.85 (1.2)	4.96 (1.2)	<.001
LV ejection fraction, mean (SD)	0.59 (0.11)	0.63 (0.09)	<.001
Systolic blood pressure, mean (SD), mm Hg	130 (18)	132 (19)	.09
Diastolic blood pressure, mean (SD), mm Hg	70 (10)	75 (10)	<.001
Weekly or more angina, No. (%)	40 (18)	131 (18)	.75
Treadmill exercise capacity, mean (SD), METs	6.3 (2.9)	7.6 (3.4)	<.001
Exercise stopped because of chest pain, No. (%)	13 (6)	21 (3)	.05

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CABG, coronary artery bypass graft; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; METs, metabolic equivalent tasks; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous coronary intervention.

SI conversion factors: To convert cholesterol to millimoles per liter, multiply by 0.0259; creatinine clearance to milliliters per second per meters squared, multiply by 0.0167; C-reactive protein to nanomoles per liter, multiply by 9.524; and NT-proBNP to nanograms per liter, multiply by 1.0.


(62%) had no angina or inducible ischemia, 129 (14%) had angina without inducible ischemia (angina alone), 188 (20%) had inducible ischemia without angina (ischemia alone), and 40 (4%) had both angina and inducible ischemia. Coronary heart disease events occurred in 7% of participants without angina or inducible ischemia, 10% of those with angina alone, 21% of those with inducible ischemia alone, and 23% of those with both angina and inducible ischemia ( $P < .001$ ). The presence of angina alone was not associated with CHD events (**Table 2**). However, the presence of inducible ischemia alone was strongly associated with CHD events, and participants

**Table 2. Relative Rate of MI or CHD Death, Stratified by the Presence of Self-reported Weekly or More Angina and Inducible Ischemia**

Variable	Proportion With MI or CHD Death, No./Total No. (%)	Unadjusted HR (95% CI)	P Value	Adjusted HR (95% CI) <sup>a</sup>	P Value
No angina or ischemia	42/572 (7)	1 [Reference]		1 [Reference]	
Angina alone	13/129 (10)	1.4 (0.7-2.6)	.27	1.4 (0.7-2.9)	.31
Ischemia alone	39/188 (21)	2.9 (1.9-4.5)	<.001	2.2 (1.4-3.5)	.005
Angina and ischemia	9/40 (23)	3.7 (1.8-7.6)	<.001	3.2 (1.4-7.2)	.006

Abbreviations: CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.

<sup>a</sup>Adjusted for age, sex, race, history of MI, history of congestive heart failure, glycosylated hemoglobin level, creatinine clearance, left ventricular ejection fraction, systolic and diastolic blood pressure, and log C-reactive protein level.



**Figure 1.** Survival rate free of myocardial infarction or coronary heart disease death by presence of weekly angina or inducible ischemia at baseline, adjusted for age, sex, race, history of myocardial infarction, history of congestive heart failure, glycosylated hemoglobin level, creatinine clearance, left ventricular ejection fraction, systolic blood pressure, and diastolic blood pressure ( $P < .001$ ).

with both angina and inducible ischemia had the highest rate of CHD events (**Figure 1**). Further adjustment for logNT-proBNP level did not eliminate the association between inducible ischemia alone and CHD events (HR, 2.0; 95% CI, 1.2-3.2) ( $P = .005$ ) or the increased risk of events in patients with both angina and inducible ischemia (HR, 2.4; 95% CI, 1.0-5.5) ( $P = .04$ ).

Among the 228 participants with inducible ischemia, 147 (64%) underwent revascularization during the follow-up period. Patients with inducible ischemia who were not revascularized appeared to have the highest risk of CHD events (**Table 3** and **Figure 2**).

#### COMMENT

We found that 24% of patients with stable CHD had inducible ischemia, and more than 80% of these patients did not report symptoms of angina weekly or more. In addition, the presence of inducible ischemia without angina was associated with a greater than 2-fold increased risk of recurrent CHD events (MI or CHD death), while the presence of angina symptoms did not adequately predict recurrent events. This association between inducible ischemia and recurrent events was independent of traditional cardiac risk factors. Our findings suggest that

further study of the potential benefit of routine stress testing in outpatients with stable CHD, regardless of angina symptoms, may be warranted.

Although there was a trend toward worse outcomes in patients with weekly or more angina compared with patients without weekly angina, this trend did not reach statistical significance ( $P = .31$ ). This is in contrast to prior studies of angina frequency, which have shown both an increase in admission for acute coronary syndrome<sup>19</sup> and an increase in mortality<sup>19,20</sup> in patients with greater angina burden. It is possible that our study was underpowered to detect a difference in outcomes associated with angina. It is also possible that some patients may minimize their symptoms or not exert themselves to the point of developing angina. Nonetheless, our results suggest that the presence of inducible ischemia is a stronger predictor of adverse events than self-reported angina, and more than 80% of patients with inducible ischemia may not report the presence of weekly or more angina.

Several prior studies have demonstrated that patients who have inducible ischemia (with or without associated symptoms of angina) have an increased risk of adverse cardiovascular events. However, prior studies have not concurrently evaluated the predictive value of self-reported angina symptoms (outside of the stress test setting) in patients with CHD, nor have they compared the risk of recurrent events associated with self-reported angina symptoms vs inducible ischemia. Mark et al<sup>8</sup> demonstrated in a series of 1698 patients with CHD undergoing exercise EKG that those with asymptomatic ischemia during stress testing had an intermediate prognosis between those patients with no ischemia and those with symptomatic ischemia. In a study of 521 patients with CHD undergoing exercise radionuclide imaging, Panchoy et al<sup>9</sup> showed that those with symptomatic or asymptomatic ischemia during exercise had a worse prognosis than those with no ischemia and that the extent of perfusion abnormality was the most predictive of risk. Our study evaluated the prognosis of patient-reported symptoms (rather than angina experienced during a stress test) because current guidelines recommend referral for stress testing based on patient-reported symptoms.

The precise mechanism by which inducible ischemia, resulting from obstructive coronary atherosclerosis, predicts MI or death, generally resulting from rupture of a mildly stenotic plaque, is unclear. Most likely, the extent of obstructive disease predicts MI and death because patients with more extensive obstructive plaques are more

**Table 3. Relative Rate of MI or CHD Death, Stratified by the Presence of Self-reported Angina or Inducible Ischemia (With or Without Revascularization) During a Mean of 3.9 Years of Follow-up**

Variable	Proportion With MI or CHD Death, No./Total No. (%)	Unadjusted HR (95% CI)	P Value	Adjusted HR (95% CI) <sup>a</sup>	P Value
No angina or ischemia	42/572 (7)	1 [Reference]		1 [Reference]	
Angina alone	13/129 (10)	1.4 (0.7-2.6)	.27	1.4 (0.7-2.0)	.31
Ischemia with revascularization	28/147 (19)	2.8 (1.7-4.5)	<.001	2.1 (1.3-3.5)	.005
Ischemia without revascularization	20/81 (25)	3.6 (2.1-6.1)	<.001	2.6 (1.5-4.5)	<.001


Abbreviations: CHD, coronary heart disease; CI, confidence interval; HR, hazard ratio; MI, myocardial infarction.

<sup>a</sup>Adjusted for age, sex, race, history of MI, history of congestive heart failure, glycosylated hemoglobin level, creatinine clearance, left ventricular ejection fraction, systolic and diastolic blood pressure, and log C-reactive protein level.

likely to have mildly stenotic or nonstenotic plaques that are potential sites for acute coronary events.<sup>21</sup> Another possibility is that the presence of an obstructive lesion may increase the likelihood that a more proximal plaque rupture would lead to infarction. A third possibility is that the presence of obstructive plaques may limit collateral blood flow to adjacent areas affected by the ruptured plaque.

Other investigators have considered the utility of a routine stress test for identifying patients with a worse prognosis after revascularization, but none have examined the prognostic utility of routine stress testing in a broad selection of outpatients with stable CHD. Weiner et al<sup>22</sup> performed stress testing in 174 participants from the Coronary Artery Surgery Study before and 6 months after coronary artery bypass graft surgery. They found that survival 12 years after surgery was decreased in patients with both symptomatic or asymptomatic ischemia compared with those with no ischemia. In a study of 873 asymptomatic patients after coronary artery bypass graft surgery, Lauer et al<sup>2</sup> found that those with inducible ischemia were more likely to die or have a nonfatal MI compared with those without ischemia. Pfisterer et al<sup>3</sup> used radionuclide stress testing to assess 490 asymptomatic patients for the presence of ischemia who had undergone successful coronary angioplasty. Inducible ischemia was present in 28% of these asymptomatic patients and was predictive of recurrent ischemic events. However, in a study of 936 patients between 1 and 6 months after a coronary event, exercise radionuclide stress testing was found to add little prognostic information after 1 year of follow-up.<sup>23</sup>

If a routine stress test identifies a patient who may be at increased risk for adverse events, would this change the approach to management? Several studies have addressed this question. In a randomized, placebo-controlled study of 360 outpatients with asymptomatic ischemia, Pepine et al<sup>24</sup> showed that treatment with atenolol reduced the burden of asymptomatic ischemia and improved event-free survival. The Asymptomatic Cardiac Ischemia Pilot study randomized 558 patients with ischemia during stress testing to angina-guided drug therapy, angina plus ischemia-guided drug therapy, or revascularization.<sup>5</sup> At the 2-year follow-up examination, those treated with a revascularization-based strategy had the best prognosis, those in the ischemia-guided strategy had an intermediate prognosis, and those in the angina-guided strategy had the worst prognosis.



**Figure 2.** Percentage of participants who developed nonfatal myocardial infarction (MI) or coronary heart disease (CHD) death, stratified by self-reported angina or inducible ischemia with or without subsequent revascularization ( $P < .001$  for trend).

In the present study, we stratified the risk of events by whether patients underwent elective revascularization. We found that patients with inducible ischemia who underwent elective revascularization had a better prognosis than those who were not revascularized, suggesting that an aggressive treatment strategy in patients with inducible ischemia may be beneficial. However, ours was an observational study and not a randomized trial, and thus our results are subject to potential bias. For instance, sicker patients may be less likely to undergo revascularization, and such selection bias could have the appearance of improving the prognosis of patients undergoing revascularization. Moreover, the recently reported Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial suggests that revascularization may not reduce the long-term rates of adverse cardiovascular events compared with optimal medical therapy.<sup>25</sup> Thus, a randomized trial would be required to evaluate whether a strategy of routine stress testing improves patient outcomes.

There are several potential limitations to this study. First, inducible ischemia was defined by exercise testing and not confirmed anatomically by coronary angiography. However, because findings on angiography do not necessarily correlate with the risk for future acute

coronary events,<sup>26</sup> functional studies may be more predictive of subsequent events than anatomical studies of coronary disease. Second, we used the presence or absence of inducible ischemia as our predictor variable and did not further characterize the extent of ischemia evident by stress echocardiography. Although it is likely that those patients with more extensive ischemia have a poorer prognosis,<sup>9</sup> we believed that the mere presence of ischemia would be a simple and reliable indicator that would not require further expert interpretation for clinical use. Third, although our findings suggest that aggressive treatment of inducible ischemia even in the absence of self-reported angina may improve prognosis, as previously mentioned, this analysis is subject to bias and is not necessarily supported by the literature. Fourth, our findings suggest that routine stress testing in an asymptomatic patient may have some clinical utility. However, our results cannot determine whether or how often a stress test should be performed. Finally, the participants in this study were mostly urban men with known CHD, and thus our results may not generalize to women or to other patient populations.

In conclusion, in a large prospective study of outpatients with stable CHD, we have shown that inducible ischemia, in the absence of self-reported angina, is both prevalent and predicts a poor prognosis. Our findings suggest that further study into the potential benefit of routine stress testing in outpatients with stable CHD, regardless of symptoms, may be warranted.

Accepted for Publication: December 16, 2007.

Correspondence: Anil K. Gehi, MD, Division of Cardiology, Emory University Hospital, 1364 Clifton Rd NE, Ste 424, Atlanta, GA 30322 (anilgehi@gmail.com).

Author Contributions: Study concept and design: Gehi and Ali. Acquisition of data: Schiller and Whooley. Analysis and interpretation of data: Ali, Na, Schiller, and Whooley. Drafting of the manuscript: Gehi, Ali, and Na. Critical revision of the manuscript for important intellectual content: Schiller and Whooley. Statistical analysis: Ali and Na. Study supervision: Schiller and Whooley.

Financial Disclosure: None reported.

Funding/Support: This study was supported by the Department of Veterans Affairs, Washington, DC; the National Heart Lung and Blood Institute (grant R01 HL079235); the American Federation for Aging Research (Paul Beeson Scholars Program), New York, New York; the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, New Jersey; the Ischemia Research and Education Foundation; and the Nancy Kirsan Heart Research Fund, San Francisco, California.

Previous Presentation: This study was presented as an oral abstract at the American College of Cardiology Scientific Sessions; March 27, 2007; New Orleans, Louisiana.

## REFERENCES

- Gibbons RJ, Balady GJ, Bricker JT, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart

- Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *Circulation*. 2002;106(14):1883-1892.
- Lauer MS, Lytle B, Pashkow F, Snader CE, Marwick TH. Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting. *Lancet*. 1998;351(9103):615-622.
- Pfisterer M, Rickenbacher P, Kiowski W, Muller-Brand J, Burkart F. Silent ischemia after percutaneous transluminal coronary angioplasty: incidence and prognostic significance. *J Am Coll Cardiol*. 1993;22(5):1446-1454.
- Zellweger MJ, Hachamovitch R, Kang X, et al. Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. *Eur Heart J*. 2004;25(7):543-550.
- Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. *Circulation*. 1997;95(8):2037-2043.
- Conti CR. Silent myocardial ischemia: prognostic significance and therapeutic implications. *Clin Cardiol*. 1988;11(12):807-811.
- Mulcahy DA. The return of silent ischaemia? not really. *Heart*. 2005;91(10):1249-1250.
- Mark DB, Hlatky MA, Califf RM, et al. Painless exercise ST deviation on the treadmill: long-term prognosis. *J Am Coll Cardiol*. 1989;14(4):885-892.
- Pancholy SB, Schalet B, Kuhlmeier V, Cave V, Heo J, Iskandrian AS. Prognostic significance of silent ischemia. *J Nucl Cardiol*. 1994;1(5, pt 1):434-440.
- Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. *Circulation*. 2003;108(10):1263-1277.
- Gehi AK, Rumsfeld JS, Liu H, Schiller NB, Whooley MA. Relation of self-reported angina pectoris to inducible myocardial ischemia in patients with known coronary artery disease: the Heart and Soul Study. *Am J Cardiol*. 2003;92(6):705-707.
- Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. *JAMA*. 2003;290(2):215-221.
- Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. *Arch Intern Med*. 2005;165(21):2508-2513.
- Gehi A, Mangano D, Pipkin S, Browner WS, Whooley MA. Depression and heart rate variability in patients with stable coronary heart disease: findings from the Heart and Soul Study. *Arch Gen Psychiatry*. 2005;62(6):661-666.
- Lee TH, Boucher CA. Clinical practice: noninvasive tests in patients with stable coronary artery disease. *N Engl J Med*. 2001;344(24):1840-1845.
- Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. *J Am Coll Cardiol*. 1995;25(2):333-341.
- Luepker RV, Apple FS, Christenson RH, et al; AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. *Circulation*. 2003;108(20):2543-2549.
- Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. *JAMA*. 2007;297(2):169-176.
- Spertus JA, Jones P, McDonell M, Fan V, Fihn SD. Health status predicts long-term outcome in outpatients with coronary disease. *Circulation*. 2002;106(1):43-49.
- Mozaffarian D, Bryson CL, Spertus JA, McDonell MB, Fihn SD. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. *Am Heart J*. 2003;146(6):1015-1022.
- Nakagomi A, Celermajer DS, Lumley T, Freedman SB. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. *Am J Cardiol*. 1996;78(5):516-519.
- Weiner DA, Ryan TJ, Parsons L, et al. Prevalence and prognostic significance of silent and symptomatic ischemia after coronary bypass surgery: a report from the Coronary Artery Surgery Study (CASS) randomized population. *J Am Coll Cardiol*. 1991;18(2):343-348.
- Krone RJ, Gregory JJ, Freedland KE, et al; Multicenter Myocardial Ischemia Research Group. Limited usefulness of exercise testing and thallium scintigraphy in evaluation of ambulatory patients several months after recovery from an acute coronary event. *J Am Coll Cardiol*. 1994;24(5):1274-1281.
- Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia Study (ASIST). *Circulation*. 1994;90(2):762-768.
- Boden WE, O'Rourke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007;356(15):1503-1516.
- Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. *J Am Coll Cardiol*. 1988;12(1):56-62.